A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma

NCT01308684 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DRUG: RO5323441 + bevacizumab [Avastin]
DRUG: bevacizumab [Avastin]

Sponsor

Hoffmann-La Roche